IP Library Granted Patent US 7,790,680
Granted Patent B2
US 7,790,680 · App. 10/507,956 · Granted Sep 7, 2010

Stable pharmaceutical composition containing factor VIII

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,790,680
App. No.
10/507,956
Granted
Sep 7, 2010
Kind
B2
Abstract

The invention relates to a stable solid pharmaceutical composition comprising factor VIII. Such a composition is devoid of amino acids and comprises: (a) factor VIII; (b) a surfactant; (c) calcium chloride; (d) sucrose; (e) sodium chloride; (f) trisodium citrate; and (g) a buffer devoid of amino acids; and has a pH from 6 to 8 prior to lyophilization and after reconstitution in water for injection. The invention also relates to the liquid pharmaceutical composition obtainable after dilution of said stable solid pharmaceutical composition with sterile water optionally containing sodium chloride.

Claims (22)

1. A solid pharmaceutical composition comprising a lyophilized solution devoid of amino acids, wherein said solution comprises:

(a) mature recombinant porcine factor VIII, wherein said mature recombinant porcine factor VIII extends from amino acid residue 20 to amino acid residue 1467 of;

(b) a surfactant;

(c) calcium chloride;

(d) sucrose;

(e) sodium chloride;

(f) trisodium citrate; and

(g) a buffer devoid of amino acids;

wherein said solution has a pH from 6 to 8 prior to lyophilization and wherein said solid pharmaceutical composition results in a solution having a pH from 6 to 8 after reconstitution in water for injection.

2. The solid pharmaceutical composition of claim 1 wherein the surfactant is polysorbate.

3. The solid pharmaceutical composition of claim 2 wherein the surfactant is a polysorbate 80.

4. The solid pharmaceutical composition of claim 1 wherein the buffer devoid of amino acids is TRIS(hydroxymethyl)methylamine.

5. The solid pharmaceutical composition of claim 1 wherein the solution devoid of amino acids has a pH from 6.5 to 7.5 prior to lyophilization and wherein said solid pharmaceutical composition results in a solution having a pH from 6.5 to 7.5 after reconstitution in water for injection.

6. The solid pharmaceutical composition of claim 1 , wherein the solution devoid of amino acids comprises:

(a) a concentration of factor VIII from 50 to 10,000 porcine units/ml for mature recombinant porcine factor VIII;

(b) a concentration of surfactant from above critical micellar concentration to 1% v/v;

(c) a concentration of calcium chloride from 0.5 to 10 mM;

(d) a concentration of sucrose from 5 to 50 mM;

(e) a concentration of sodium chloride from 0.15 to 0.5 M;

(f) a concentration of trisodium citrate from 1 to 50 mM; and

(g) a concentration of a buffer devoid of amino acids from 1 to 50 mM.

7. The liquid pharmaceutical composition obtainable after dilution of a solid pharmaceutical composition of claim 1 with sterile water optionally containing sodium chloride.

Assignments (7)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 31, 2021
From: BAXALTA GMBH; BAXALTA INCORPORATED
To: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Reel/Frame 055189/0177 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 24, 2017
From: BAXTER INTERNATIONAL INC.; BAXTER HEALTHCARE SA
To: BAXALTA INCORPORATED; BAXALTA GMBH
Reel/Frame 041734/0862 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNOR NAME PREVIOUSLY RECORDED ON REEL 296336 FRAME 0777. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Jan 5, 2016
From: SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES, S.A.S.
To: IPSEN PHARMA S.A.S.
Reel/Frame 037430/0194 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 23, 2013
From: IPSEN PHARMA S.A.S.
To: BAXTER INTERNATIONAL INC.; BAXTER HEALTHCARE S.A.
Reel/Frame 030861/0559 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ADDRESS PREVIOUSLY RECORDED ON REEL 023034 FRAME 0251. ASSIGNOR(S) HEREBY CONFIRMS THE ADDRESS SHOULD BE 65 QUAI GEORGES GORSE, 92100 BOULOGNE-BILLANCOURT, FRANCE. Recorded Jan 16, 2013
From: SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATION SCIENTIFIQUES (S.C.R.A.S.)
To: IPSEN PHARMA S.A.S.
Reel/Frame 029636/0777 →
CHANGE OF NAME Recorded Jul 31, 2009
From: SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATION SCIENTIFIQUES (S.C.R.A.S.)
To: IPSEN PHARMA S.A.S.
Reel/Frame 023034/0251 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 14, 2004
From: WHITE, MARY; WEBB, PAUL
To: SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.)
Reel/Frame 016710/0034 →